LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids
IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model IMAN is the world’s first...
top of page
Welcome to LIfT BioSciences
LIfT BioSciences is developing a breakthrough allogeneic innate cell therapy platform that produces different types of Immunomodulatory Alpha Neutrophils (IMANs). LIfT's focus is on producing an exceptional type of anti-cancer alpha neutrophil with enhanced cytotoxic and immunomodulatory properties.
Our mission is to develop affordable curative therapies for solid tumours with high unmet medical need.
bottom of page